Back to results
US 11,980,535 B2Granted
Method of using a cardiovascular graft to reduce thrombosis or platelet adhesion
AssigneeXeltis AG
InventorsLuke David Burke, Martijn Antonius Johannes Cox, Aurelie Serrero
Life of this patent
Estimating the term…
Abstract
A cardiovascular graft is provided with highly reduced thrombogenicity. The cardiovascular graft is an electrospun non-woven mesh produced from supramolecular polymers with large diameter fibers. The cardiovascular graft can be implemented as a vascular graft into the human body to allow vascular bypass/reconstruction, or repeated venous access for dialysis treatment, as well as other disorders of small-diameter blood vessels.
Claims13
A method of using a cardiovascular graft to reduce platelet adhesion, comprising:
- having a cardiovascular graft designed as a tubular structure with an inner wall made out of a fibrous network of supramolecular compounds having hard-blocks covalently bonded with soft-blocks, wherein the hard-blocks comprise 2-ureido-4[1H]-pyrimidinone (UPy) compounds, wherein the fibrous network is a bioresorbable electrospun non-woven fibrous network with fibers having an average fiber diameter of 1-10 microns, and wherein the tubular structure has an inner diameter between 2-8 mm, and an inner wall thickness of 20-900 micrometers, wherein the soft-blocks comprise a polyurethane, polycarbonate, poly(ortho)ester, polyphosphoester, polyanhydride, polyphosphazene, polyhydroxyalkanoate, polyvinylalcohol, polypropylenefumarate or any combination thereof;
- and
- using the cardiovascular graft to reduce platelet adhesion upon implantation of the cardiovascular graft in a human body.
Dependencies are inferred from the claim text.